Cellectar biosciences and u.s.-based nusano enter into multi-isotope supply agreement

Partnership provides long-term supply of iodine-125 and actinium-225 supports advancement of radiotherapeutic pipeline and plans to initiate phase 1b clinical trial of clr-125 for triple-negative breast cancer florham park, n.j. and west valley city, utah, june 26, 2025 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and nusano, a physics company transforming the production of radioisotopes, today announced the signing of a multi-year supply agreement in which nusano will provide cellectar with iodine-125 (i-125) and actinium-225 (ac-225) for its clinical studies and future commercial needs.
CLRB Ratings Summary
CLRB Quant Ranking